New data on Symbicort as a potential anti-inflammatory reliever in mild asthma to be presented at ATS 2019
A total of 73 abstracts to be presented at ATS 2019 International Conference from across AstraZeneca’s respiratory portfolioNew data from the Symbicort Turbuhaler (budesonide/formoterol) Novel START trial is among 73 AstraZeneca abstracts accepted for oral or poster presentation at the American Thoracic Society (ATS) 2019 International Conference,17-22 May in Dallas, US. Novel START, an open-label trial designed to reflect real-world practice, assesses the effectiveness of Symbicort Turbuhaler as a potential anti-inflammatory reliever taken as-needed, compared with two of the most